For the quarter ending 2025-12-31, ANEB made $3,257,896 in revenue. -$1,999,397 in net income. Net profit margin of -61.37%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Research and development | 1,164,737 | 809,991 | 1,074,985.25 | |
| General and administrative | 1,455,173 | 1,450,269 | 1,230,885 | |
| Total operating expenses | 2,619,910 | 2,260,260 | 2,305,870.25 | |
| Loss from operations | -2,619,910 | -2,260,260 | -2,305,870.25 | |
| Interest expense | 17,439 | 17,439 | 95,503.5 | |
| Interest income | 85,410 | 109,616 | 64,478.25 | |
| Grant income | 552,576 | 9,825 | 216,003.5 | |
| Other | -34 | -96 | -298.75 | |
| Other income, net | 620,513 | 101,906 | 184,679.5 | |
| Net loss | -1,999,397 | -2,158,354 | -2,121,190.75 | |
| Net loss per share, basic | -0.05 | -0.05 | -0.063 | |
| Net loss per share, diluted | -0.05 | -0.05 | -0.063 | |
| Weighted average common shares outstanding, basic | 41,084,731 | 41,084,731 | 8,455,076.5 | |
| Weighted average common shares outstanding, diluted | 41,084,731 | 41,084,731 | 8,455,076.5 | |
Anebulo Pharmaceuticals, Inc. (ANEB)
Anebulo Pharmaceuticals, Inc. (ANEB)